KalVista Pharmaceuticals Inc. has announced its financial results for the fiscal quarter ending July 31, 2025. The company reported $1.4 million in net product revenue for the three months, attributed to the US sales of EKTERLY, which became commercially available in mid-July following FDA approval. This marks a significant milestone as EKTERLY is the first and only oral on-demand treatment for hereditary angioedema $(HAE)$. The cost of revenue for the same period was $0.6 million, reflecting EKTERLY manufacturing and inventory overhead costs following US approval. There were no product sales recorded in the previous fiscal year, and thus no cost of revenue was recognized for the same period in 2024. Selling, general, and administrative expenses increased to $44.7 million from $17.6 million in the same quarter of the previous year, primarily due to commercialization expenses related to EKTERLY. Research and development expenses decreased to $15.2 million from $26.6 million, as clinical trial expenses reduced and some pre-commercial awareness expenses for EKTERLY were reclassified under selling, general, and administrative expenses. KalVista reported having cash, cash equivalents, and marketable securities totaling approximately $191.5 million as of July 31, 2025. The company has received 460 patient start forms for EKTERLY within eight weeks of its approval, representing nearly five percent of the reported HAE patient population in the US, which indicates substantial early demand. The company did not provide specific guidance or outlook in the financial results report.